Taxonomie & Artenidentifikation

Molekulare Systematik, morphologische Identifikation und regulatorische Implikationen des <em>Hirudo medicinalis</em>-Artenkomplexes

Zuletzt aktualisiert: May 26, 2026Geprüft von: Andrei Dokukin, MD

Descriptive biologyEducational reference

Taxonomy context: Three species (H. medicinalis, H. verbana, H. orientalis) underpin 440+ catalogued salivary proteins. See the Coverage Map for what is and isn't studied per condition, and the Research Roadmap for ASH's gap priorities.

Diese Seite präsentiert die taxonomische Klassifikation und Artenidentifikation medizinischer Blutegel basierend auf peer-reviewter Systematik, molekularer Phylogenetik und vergleichender Genomik. Die Identifikation auf Artenebene hat direkte Auswirkungen auf die regulatorische FDA-Konformität: 510(k)-Zulassungen verweisen auf „Hirudo medicinalis", aber molekulare Beweise zeigen, dass kommerziell gelieferte Blutegel überwiegend H. verbana sind. Die Daten stammen aus Taxonomie-, Molekularbiologie- und Regulierungsliteratur, die den Zeitraum 1758–2024 umfasst.

Zuletzt aktualisiert: June 18, 2026

FDA-zugelassene Indikation

Medizinische Blutegel sind Süßwasser-Ringelwürmer aus der Gattung Hirudo Linnaeus, 1758. Sie sind auf allen Kontinenten außer der Antarktis verbreitet. Von etwa 650 beschriebenen Süßwasser-Blutegelarten sind nur einige Dutzend obligate Hämatophagen. Unter diesen bilden drei eng verwandte Arten — H. medicinalis, H. verbana und H. orientalis — den „medizinischen Blutegel-Artenkomplex", der in der klinischen Hirudotherapie verwendet und von der FDA als 510(k)-Medizinprodukt zugelassen wurde. Die Taxonomie dieses Komplexes hat seit 2005 eine grundlegende Revision erfahren: Was lange als eine einzige polymorphe Art mit drei Unterarten galt, wurde durch mitochondriale und nukleäre DNA-Analyse als drei verschiedene Arten mit allopatrischen Verbreitungsgebieten, subtilen morphologischen Unterschieden und potenziell divergierenden pharmakologischen Profilen nachgewiesen. Dieses Artenproblem hat tiefgreifende Auswirkungen auf die regulatorische Dokumentation, klinische Standardisierung und pharmakologische Forschung.

Diese Seite bietet eine vollständige Behandlung der Taxonomie medizinischer Blutegel: die formale hierarchische Klassifikation mit historischen Autoritäten, die wegweisende molekulare Revision durch Siddall et al. (2007), vergleichende Speicheldrüsen-Transkriptomik durch Babenko et al. (2020), FDA-Lieferanten mit FDA-510(k)-Freigabe und ihre 510(k)-Zulassungen, morphologische Identifikationsschlüssel, gefährliche Verwechslungsarten, durch Moquin-Tandon (1846) dokumentierte Farbvariationen, globale Vielfalt hämatophager Blutegel, molekulare Identifikationsmethoden (COI-Barcoding) und die klinische Bedeutung einer genauen Artenidentifikation für regulatorische Konformität und pharmakologische Reproduzierbarkeit.

Formale taxonomische Klassifikation

Die Gattung Hirudo wurde erstmals von Carl Linnaeus in der 10. Auflage des Systema Naturae (1758) benannt, mit H. medicinalis als Typusart. Die formale Klassifikation wurde durch Monografien des 19. Jahrhunderts von Moquin-Tandon (1827, 1846), Grube (1844), Leuckart (1863) und Metschnikoff (1871) verfeinert, wobei der moderne Rahmen auf Familienebene durch Whitman (1878, 1886, 1887) etabliert wurde. Anschließende Beiträge von Bergh (1885), Apathy (1888), Cuenot (1891), Sukatschoff (1903), Livanov (1940), Lukin (1976) und das enzyklopädische Werk von Sawyer (1986) vervollständigten die prämolekulare Taxonomie der Hirudinidae.

Rang	Taxon	Autorität	Anmerkungen
Stamm	Annelida	Lamarck, 1809	Segmentierte Würmer; ~22.000 Arten. Blutegel sind die am stärksten abgeleitete Klade innerhalb der Annelida
Klasse	Hirudinea	Lamarck, 1818	Alle Blutegel; ~680 Arten weltweit. Feste Segmentanzahl (32 echte Somite), Vorder- und Hintersaugnapf, hermaphroditische Reproduktion
Unterklasse	Archihirudinea	Lukin, 1956	Primitive kieferbewehrte Blutegel mit angestammter Kiefermorphologie. Von Euhirudinea unterschieden durch Kieferstruktur und reproduktive Anatomie
Ordnung	Arhynchobdellida	Blanchard, 1894	Kieferbewehrte Blutegel mit drei muskulösen Kiefern in triradiatem Muster (das „Mercedes-Benz-Zeichen„ als Bissspur); ~100 Zähne pro Kiefer
Familie	Hirudinidae	Whitman, 1878	Obligate sanguivore (blutfressende) Blutegel mit hochentwickelten Speicheldrüsen; umfasst alle „echten" medizinischen Blutegel. Begründet von C.O. Whitman in seiner wegweisenden Monografie
Unterfamilie	Hirudininae	Blanchard, 1892	Medizinische Blutegel der Alten Welt mit paarigen dorsalen Längsstreifen; von den Macrobdellinae der Neuen Welt durch Kieferzahnung und Pigmentierung unterschieden
Gattung	Hirudo L.	Linnaeus, 1758	Drei anerkannte medizinische Arten plus mehrere nichtmedizinische Vertreter der Gattung. Verbreitet über die Paläarktis von Skandinavien bis Zentralasien
Typusart	Hirudo medicinalis	Linnaeus, 1758	Die nominotypische Art. Nordeuropäisches Verbreitungsgebiet. CITES Anhang II; Europäische Rote Liste (potenziell gefährdet). Selten in der aktuellen kommerziellen Versorgung

Die obige hierarchische Klassifikation folgt dem in der FDA-510(k)-Dokumentation verwendeten System. Regulatorische Einreichungen beziehen sich auf die Gattung Hirudo und die Art H. medicinalis, obwohl molekulare Evidenz (Abschnitt 2) zeigt, dass die meisten kommerziell gelieferten Blutegel zu H. verbana gehören. Ob diese Diskrepanz pharmakologische Bedeutung hat, bleibt eine offene Forschungsfrage (Babenko et al., 2020).

Wichtige taxonomische Autoritäten — historische Zeitleiste

Jahr	Autor	Beitrag
1758	Linnaeus	Systema Naturae, 10. Aufl. — formale Beschreibung der Gattung Hirudo und Art H. medicinalis
1820	Carena	Erstbeschreibung von H. verbana anhand südeuropäischer Exemplare (Lago-Verbano-/Lago-Maggiore-Region)
1827	Moquin-Tandon	Monographie de la famille des Hirudinées — erste umfassende Blutegel-Monografie
1844	Grube	Erweiterte morphologische Beschreibungen europäischer Hirudinea
1846	Moquin-Tandon	Dokumentierte 19 Farbvarianten innerhalb von H. medicinalis; etablierte die Farbenmuster-Taxonomie
1863	Leuckart	Detailed internal anatomy and Reproduktionsbiologie of Hirudinea
1871	Metschnikoff	Embryologische Studien; vergleichende Entwicklungsmorphologie
1878, 1886, 1887	Whitman	Etablierte die Familie Hirudinidae; legte den Grundstein für die moderne Blutegel-Taxonomie mit drei wegweisenden Publikationen
1885	Bergh	Vergleichende Histologie von Blutegelgeweben
1888	Apathie	Neuroanatomie- und Bindegewebsstudien an Hirudinea
1891	Cuenot	Physiologische Studien zu Blutegelblut und Exkretionssystemen
1903	Sukatschoff	Russische Blutegelfauna; frühe Beschreibungen östlicher Populationen, später als H. orientalis erkannt
1940	Livanov	Sowjet-Ära-Blutegelsystematik; paläarktische Verbreitungsmuster
1956	Lukin	Etablierte die Unterklasse Archihirudinea; reorganisierte die höhere Blutegel-Klassifikation
1976	Lukin	Aktualisierte sowjetische Blutegel-Monografie unter Integration ökologischer und biogeografischer Daten
1986	Sawyer	Definitive pre-molecular reference: ~650 freshwater species cataloged. Species-level keys, global biogeography, ecology, and medical applications. The single most cited taxonomic work in leech biology
2004	Baskova	Recognized three subspecies: H. m. medicinalis (therapeutic), H. m. officinalis (apothecary), H. m. orientalis (eastern). Later revised by molecular evidence
2005	Utevsky & Trontelj	Formal description of H. orientalis sp. nov. from Turkish/Central Asian specimens
2007	Siddall et al.	Landmark molecular revision: mtDNA COI + nuclear markers proved 3 distinct species, not subspecies. Overturned 200+ years of single-species taxonomy

Das Artenproblem: H. medicinalis vs. H. verbana vs. H. orientalis

For over two Jahrhunderte, the medizinischer Blutegel was treated as a single species, Hirudo medicinalis Linnaeus, 1758, with geographic variation expressed as subspecies or color morphs. The Russian tradition (Baskova, 2004) recognized three subspecies: H. medicinalis medicinalis (the „therapeutic“ or northern form), H. medicinalis officinalis (the „apothecary“ or southern European form), and H. medicinalis orientalis (the eastern form from Turkey, Iran, and Central Asia). This subspecific framework was used in Russian hirudotherapy literature through the early 2000s and remains referenced in some CIS klinisch protocols.

Siddall et al. 2007 — The Landmark Molecular Revision

In 2007, Mark Siddall and colleagues at the American Museum of Natural History published a significant Studie in Proceedings of the Royal Society B that fundamentally altered the taxonomy of medizinische Blutegel. Using mitochondrial DNA (cytochrome oxidase subunit I, COI) sequencing combined with nuclear marker analysis across Hirudo populations from throughout the Palearctic range, they demonstrated dass die three previously recognized subspecies are in fact three distinct biological species:

Genetic divergence between the three lineages exceeds the threshold recognized for species-level separation in annelids
Each lineage forms a reciprocally monophyletic clade on sowohl mitochondrial and nuclear gene trees — the gold standard criterion for species delimitation
The three species show allopatric distributions with limited contact zones in the Balkans and Caucasus regions (further refined by Trontelj & Utevsky, 2012)
Morphological differences, while subtle, are konsistent mit the molecular groups — particularly in dorsal coloration, ventral pigmentation, and jaw dentition patterns

Critical regulatory implication: The majority of leeches supplied commercially under the label „Hirudo medicinalis“ — including those from the largest FDA-zugelassener Lieferant, Ricarimpex SAS — are actually H. verbana. This means that most published klinische Studien reporting outcomes with „H. medicinalis“ actually document the efficacy of H. verbana. Whether pharmacological differences zwischen Arten are clinically significant remains an open investigation question.

Die drei medizinischen Arten — detaillierte Profile

Hirudo medicinalis Linnaeus, 1758

Gebräuchlicher Name: Northern medizinischer Blutegel

Range: Restricted to northern Europe — Scandinavia, northern Germany, Baltic states, northern Russia. The most geographically restricted of the three species
Schutzstatus: CITES Appendix II (international trade regulated); European Red List (Near Threatened). Wild populations have declined dramatically since the 19th-century „leech mania“ when billions were harvested
Kommerzielle Verfügbarkeit: Rare in aktuell commercial supply. Die meisten suppliers have shifted to the more easily bred H. verbana
Morphologie: Olive-green dorsum with prominent orange-yellow longitudinal stripes; typically darker overall coloration than H. verbana; ventral surface often uniformly olive-green without significant spotting
Nomenclatural note: As the type species, H. medicinalis is the name referenced in all three FDA 510(k) clearances, regardless of actual species supplied

Hirudo verbana Carena, 1820

Gebräuchlicher Name: Southern (Hungarian) medizinischer Blutegel

Range: Southern and southeastern Europe — Mediterranean basin, Balkans, Hungary, Romania, Ukraine (south), Turkey (European part). Named after Lake Verbano (Lago Maggiore) in the Italian-Swiss border region
Kommerzielle Dominanz: The most commonly supplied species worldwide. Ricarimpex SAS (Eysines, France) and Biopharm (Swansea, Wales) sowohl primarily breed H. verbana. Virtually all klinische Studien published since the 1990s used diese Art
Klinische Bedeutung: When a published Studie reports outcomes with „H. medicinalis,“ the actual species is almost certainly H. verbana unless the Studie explicitly performed molecular verification
Morphologie: Brighter green coloration than H. medicinalis; prominent orange-yellow dorsal stripes; ventral surface characteristically pale with variable dark spots or blotches; generally considered die am stärksten colorful of the three species
Zucht-Vorteil: Adapts more readily to Zucht in Gefangenschaft conditions, with higher fecundity and faster growth rates than H. medicinalis

Hirudo orientalis Utevsky & Trontelj, 2005

Gebräuchlicher Name: Eastern (Oriental) medizinischer Blutegel

Range: Turkey, Iran, Azerbaijan, Uzbekistan, and adjacent Central Asian regions. Extends eastward to the limits of the genus Hirudo distribution
Klinischer Einsatz: Widely used in CIS countries (Russia, Ukraine, Kazakhstan, Uzbekistan) for hirudotherapy. This is the species most Russian klinische Literatur (including Baskova’s work) likely refers to when discussing the „oriental subspecies“
Taxonomic history: Formally described as a neu species by Utevsky & Trontelj (2005) based on morphological and molecular evidence. Previously classified as H. medicinalis orientalis
Morphologie: Variable coloration; dorsal stripes present but may be less pronounced than in H. medicinalis or H. verbana; ventral surface typically dark or greenish with variable spotting
FDA-Status: Not specifically cleared by FDA. No US-market supplier is known to specifically source H. orientalis, though it may be present in unverified Lieferkettes

Babenko et al. 2020 — Vergleichende Speichel-Transkriptomik

Building on the species framework established by Siddall et al. (2007), Babenko and colleagues (2020) performed die erste Genom-level comparison of all three medizinischer Blutegel species. Their Studie combined Entwurfs-Genom assembly with RNA-seq of Speicheldrüse tissue from H. medicinalis, H. verbana, and H. orientalis, producing die am stärksten thorough molecular comparison of the species complex to date.

Key Findings

Breit konserviertes Speichel-Repertoire: All three species express the core set of bioaktive Moleküle essenziell for Blutfütterung — M12 and M13 metalloprotease families, CRISP (cysteine-rich secretory) Proteine, apyrase, adenosine deaminase, cystatins, hyaluronidase, and ficolins
Unterschiedliche Expressionsmuster: Despite the conserved repertoire, quantitative expression levels of specific gene families differ zwischen Arten. This raises the possibility that salivary pharmacological potency may vary zwischen Arten, even if the qualitative composition is ähnlich
Entwurfs-Genomsequenzen: Assembly statistics provided for all three species, enabling zukünftig Studien to identify artspezifisch regulatory elements, gene duplications, and pseudogenes
M12/M13 metalloprotease expansion: Both protease families show evidence of lineage-specific duplications, suggesting that extrazelluläre Matrix degradation — a key function during Blutfütterung — may be under positive selection
Konservierung der Kern-Antikoagulationsmaschinerie: Hirudin, destabilase, and der/die wichtigste thrombin/Faktor-Xa-Inhibitoren are present in all three species at sowohl transcript and predicted Protein levels

Clinical interpretation: The Babenko et al. (2020) findings suggest dass die three medizinischer Blutegel species have broadly equivalent pharmacological potenziell for the FDA-zugelassenen indications (venöse Kongestion relief). However, the verschiedeneial expression patterns leave open the possibility that species choice could matter for specific non-cleared Forschung applications targeting particular bioaktive Moleküle. This remains an active investigation question with no definitive klinisch answer.

Molekulare Identifikationsmethoden

Morphological identification of Hirudo species is unreliable aufgrund extensive intraspecific color variation and subtle interspecific differences. Molecular methods provide die einzige definitive species identification. The standard approach uses DNA barcoding with the mitochondrial cytochrome oxidase subunit I (COI) gene.

COI-Barcoding-Protokoll

Parameter	Standardansatz
Zielgen	Cytochrom-Oxidase-Untereinheit I (COI / cox1)
Fragmentlänge	~658 bp (Folmer-Region) — das universelle DNA-Barcode-Fragment
Primer	LCO1490 / HCO2198 (Folmer et al., 1994) — universal invertebrate COI primers
Probenquelle	Hintersaugnapf tissue clip (non-lethal) or whole-body DNA extraction
Referenz-Datenbank	BOLD (Barcode of Life Database) und GenBank; Referenzsequenzen hinterlegt von Siddall et al. (2007) und Folgestudien
Interspezifische Divergenz	Typically 5–10% between H. medicinalis, H. verbana, and H. orientalis — well above the 2–3% barcoding gap threshold
Bearbeitungszeit	2–5 working days from tissue sample to species ID (standard Sanger sequencing)
Supplementary markers	Nuclear ITS (internal transcribed spacer) for confirmation in ambiguous cases; multilocus approaches empfohlen for phylogeographic studies

DNA barcoding is now the gold standard for medizinischer Blutegel species verification. The method is straightforward, inexpensive ($30–50 per sample at commercial sequencing facilities), and definitive. For klinisch and regulatory purposes, COI barcoding provides unambiguous identification where morphology cannot.

No aktuell FDA 510(k) clearance requires molecular species verification as a condition of supply. However, as awareness of the species problem grows, institutional quality assurance programs may begin incorporating periodic COI barcoding of incoming leech shipments — particularly in academic medical centers conducting Forschung alongside klinischer Einsatz.

FDA-Lieferanten mit FDA-510(k)-Freigabe & Regulierungsrahmen

Medizinische Blutegel sind classified by the FDA as FDA 510(k)-cleared medical devices under product code NRN. They require 510(k) premarket notification (not PMA approval) and are cleared for prescriptive, single-use application. As of 2024, three suppliers hold active 510(k) clearances.

FDA-510(k)-Lieferanten mit FDA-510(k)-Freigabe medizinischer Blutegel
Studie	Design	Population (n=)	Intervention	Primäres Outcome	Ergebnis
Ricarimpex SAS 2004	FDA 510(k) clearance	Medicinal leeches (Hirudo sp.) bred at Eysines facility, France (n=NR)	510(k) K040187 — First FDA clearance of medicinal leeches as FDA-cleared medical device	Two cleared indications: (1) adjunct to healing of graft tissue with venous congestion, (2) creating prolonged localized bleeding to relieve venous congestion	Cleared 2004. Ricarimpex is the primary global supplier; most clinical studies in the literature sourced leeches from this facility Prescriptive use, single-use only. Species listed as H. medicinalis but per Siddall et al. 2007, likely H. verbana
Biopharm (UK) Ltd. 2014	FDA 510(k) clearance	Medicinal leeches bred at Hendy facility, Swansea, Wales, UK (n=NR)	510(k) K132958 — FDA clearance for medicinal leeches as FDA-cleared medical device	Same two indications as K040187: venous congestion adjunct and prolonged localized bleeding	Cleared approximately 2014. Second international supplier with FDA market access; supplies both UK and US hospitals Biopharm breeds leeches under pharmaceutical-grade conditions; Roy Sawyer (author of 1986 monograph) founded this company
Carolina Biological Supply Co. 2015	FDA 510(k) clearance	Medicinal leeches distributed from Burlington, North Carolina, USA (n=NR)	510(k) K140907 — FDA clearance for medicinal leeches as FDA-cleared medical device	Same cleared indications: venous congestion adjunct and prolonged localized bleeding	Cleared 2015. First US-based supplier with 510(k) clearance; reduces supply chain delays for domestic hospitals Carolina Biological is primarily known as a science education supplier; their FDA-cleared medical leech line represents a distinct product category

Zugelassene Indikationen (alle drei 510(k)-Zulassungen)

Venous congestion adjunct: As an adjunct to the healing of graft/flap tissue when problems of venöse Kongestion may delay healing or cause tissue necrosis
Prolonged localized bleeding: For overcoming problems of venöse Kongestion by creating prolonged, localized bleeding at the site of application

Regulatorische Klassifikationsdetails

Parameter	Value
Geräteklasse	Pre-Amendment (510(k) erforderlich)
Product code	NRN
Regulation number	878.4910
Clearance pathway	510(k)-Vor-Markt-Anzeige
Nutzungsbeschränkung	Prescriptive use only (requires physician order)
Wiederverwendungsrichtlinie	Single-use only — leeches must be humanely euthanized after application (70% ethanol immersion or freezing)
Referenzierte Art	Hirudo medicinalis (Hinweis: die tatsächlich gelieferte Art ist überwiegend H. verbana)

The discrepancy between the species referenced in 510(k) documentation (H. medicinalis) and the species actually supplied (H. verbana) wurde noted in the literature (Siddall et al., 2007) but has not prompted FDA regulatory action to date. The comparative transcriptomic data from Babenko et al. (2020) — showing broadly ähnlich salivary profiles — may provide scientific justification for treating the species as functionally equivalent for the cleared indications. However, formal bioequivalence Studien wurden nicht conducted.

Morphological Identification & Diagnostic Features

While molecular methods provide definitive species identification, morphological assessment remains der erste-line approach in klinische Umfelder and field work. The following diagnostic features are used to identify medizinische Blutegel and distinguish them from dangerous look-alike species.

Primäre diagnostische Merkmale

Merkmal	Beschreibung	Diagnostischer Wert
Dorsale Streifen	Orange-yellow longitudinal stripes running the length of the dorsum, typically 2–6 prominent stripes with variable accessory markings	Zuverlässigstes Feld-Identifikationsmerkmal. Present in all three Hirudo species; absent in dangerous look-alikes
Grundfärbung	Olive-green ground color with variable shades from dark forest green to bright yellowish-green, depending on species, age, feeding state, and individual variation	Useful but highly variable; not reliable for species-level identification alone (see Moquin-Tandon 19 variations)
Ventrale Oberfläche	Pale, dark, or green; may feature dark/black spots. H. verbana typically shows pale ventral with scattered spots; H. medicinalis tends toward uniform olive-green	Ventral pattern differences may assist in provisional species assignment but require molecular confirmation
Körpergröße	Large: >10 cm (extended); Medium: 3–8 cm. Maximum documented: 44 cm / 38.8 g (Shchegolev & Fedorova, captive specimen)	Size varies enormously with age and feeding state; fasting adults average 2–3 g; engorged specimens reach 10–15 g (5× Körpergewicht in blood)
Kieferapparat	Three muscular jaws arranged in triradiate (Y-shaped) pattern; each jaw bearing ~80–100 sharp teeth. Produces characteristic „Mercedes-Benz sign“ bite mark	Jaw strength and tooth count distinguish Hirudo from jawless leeches and from Limnatis nilotica (weak jaws, 27–45 teeth)
Annulation	Each true somite divided into 5 annuli (rings); total body annuli typically 95–102; head end narrower, posterior broader with large caudal sucker	Anzahl der Annuli hilft bei der Gattungs-Identifikation; innerhalb Hirudinidae konsistent
Sensorische Papillen	Segmentally arranged sensory papillae on dorsal surface; 5 Augenpaare on anterior segments arranged in a dorsal arc	Eye arrangement pattern aids in family-level identification; consistent across Hirudo

Referenzdaten zu Größe und Gewicht

Zustand	Länge (cm)	Gewicht (g)	Anmerkungen
Nüchterner Adulter (typisch)	8–12	2–3	Standard-Klinikgröße; die meisten Lieferanten versenden Blutegel in diesem Bereich
Medium (subadult)	3–8	0.5–1.5	Verwendet in delikaten Anwendungen (Ophthalmologie, Pädiatrie)
Vollgesogen (nach Fütterung)	10–15	10–15	Ingests 5–15 mL blood per feeding; up to 5× Körpergewicht. Detaches spontaneously after 20–45 minutes
Maximum recorded	44	38.8	Shchegolev & Fedorova; captive-raised specimen under optimized laboratory conditions

Color Variation — The 19 Moquin-Tandon Varieties (1846)

Alfred Moquin-Tandon, in his 1846 monograph on the Hirudinea, documented 19 distinct color variations within what was then classified as Hirudo medicinalis. This remarkable phenotypic diversity, recorded before the concepts of cryptic species or subspecies were well established, reflects three sources of variation: (1) genuine intraspecific polymorphism within each species, (2) interspecific differences between H. medicinalis, H. verbana, and H. orientalis (unknowingly mixed in 19th-century collections), and (3) ontogenetic and condition-dependent changes (age, feeding status, water chemistry).

Moquin-Tandon’s classification remains historisch significant and is still cited in modern taxonomic literature as evidence that color alone is insufficient for species-level identification. His varieties encompassed the full spectrum from nearly black specimens to bright green individuals with vivid orange stripes, and included variations in dorsal stripe number, width, and intensity; ventral coloration ranging from pale cream to nearly black; and the presence, absence, and distribution of spots and blotches.

Dorsales Grundfarben-Spektrum

Dunkel olivgrün (am häufigsten)
Hell olivgrün
Gelblich-grün
Braungrün
Dunkelbraun, fast schwarz
Rotbraun (selten)

Dorsale Streifenmuster

Breite, kräftige orange-gelbe gepaarte Streifen
Schmale, blasse Streifen (kaum sichtbar)
Unterbrochene/fragmentierte Streifen
Mehrere akzessorische laterale Streifen
Zusammenfließende Streifen, die in eine dorsale Bande übergehen
Orangerot-Streifen-Variante (selten)

Ventrale Oberflächenmuster

Blass-cremefarben bis gelblich (am häufigsten bei H. verbana)
Einheitlich olivgrün (typisch H. medicinalis)
Dunkel grünlich-schwarz
Verstreute dunkle Flecken auf blassem Untergrund
Dichte Fleckung, fast einheitlich dunkel
Lateral margin color verschiedene from ventral center

Modern interpretation: Einige der Moquin-Tandon’s 19 varieties likely represent verschiedene species within the Hirudo complex (particularly the distinction between pale-ventral „verbana-type“ and dark-ventral „medicinalis-type“ specimens), while others reflect genuine within-species polymorphism. Only molecular identification can resolve this ambiguity. The practical lesson for clinicians: the species of a medizinischer Blutegel cannot be determined by visual inspection alone.

Dangerous Look-Alike Species — Safety-Critical Identification

Patient safety alert: Two non-medizinischer Blutegel species share habitats with Hirudo and may be accidentally collected or misidentified. One of these — Limnatis nilotica (the Nile horse leech) — is a dangerous parasite that causes hemorrhage, hemoptysis, and potenziellly fatal suffocation. Correct identification is a non-negotiable safety requirement for any practitioner collecting leeches from wild or semi-Wildpopulationen.

Limnatis nilotica (Savigny, 1822) — Nil-/Ägyptischer Pferdeegel

Limnatis nilotica is the single most dangerous Blutegelart that could be confused with a medizinischer Blutegel. Unlike Hirudo, which feeds from the external skin surface, Limnatis nilotica enters body cavities (nose, pharynx, larynx, vagina, urethra, rectum) and attaches to mucosal surfaces. Its small, weak jaws (27–45 teeth per jaw, verglichen mit 80–100 in Hirudo) are adapted for thin mucosal tissue, not skin.

Klinische Gefahren

Hämorrhagie: Persistent mucosal bleeding from attachment site; Speichel-Antikoagulantien prevent clotting
Hämoptyse: When attached in the pharynx or larynx, causes coughing of blood
Atemwegsobstruktion: Pharyngeal/laryngeal attachment can cause suffocation — documented fatal cases in the medical literature
Anämie: Prolonged undetected attachment causes chronic blood loss anemia

How to Distinguish from Hirudo

Merkmal	Hirudo (medizinisch)	Limnatis nilotica (gefährlich)
Dorsale Streifen	PRESENT — orange-yellow longitudinal stripes (the single most reliable distinguishing character)	ABSENT — no dorsal longitudinal stripes
Laterale Streifen	Orange-gelbe Streifen sind DORSAL, nicht lateral	Orange lateral stripes PRESENT (lateral, not dorsal — opposite position from Hirudo)
Kieferstärke	Starke muskulöse Kiefer; 80–100 Zähne pro Kiefer; durchdringen leicht intakte Haut	Schwache Kiefer; 27–45 Zähne pro Kiefer; können nur dünne Schleimhautflächen durchdringen
Fressverhalten	Heftet sich an die äußere Hautoberfläche; löst sich nach Sättigung spontan ab	Enters body cavities (nose, pharynx, etc.); attaches to mucosal surfaces internally
Gesamtfärbung	Olive-green with stripe pattern; distinct dorsal/ventral color verschiedeneiation	Uniform brownish-olive or brownish-green; less distinct dorsal/ventral verschiedeneiation
Geografisches Verbreitungsgebiet	Europa, Türkei, Zentralasien	Nordafrika (Nilbecken), Naher Osten, südliches Europa (Mittelmeerraum)

Haemopis sanguisuga (Linnaeus, 1758) — Falscher Pferdeegel

Haemopis sanguisuga, despite its alarming species epithet („blood-sucker“), is not a blutfressend species. It is a predator of invertebrates (earthworms, insect larvae, snails) and shares freshwater habitats with Hirudo across much of Europe and western Asia. While not directly dangerous, its misidentification as a medizinischer Blutegel would result in therapeutic failure — it produces no Antikoagulans secretion and cannot feed from human skin.

Unterscheidungsmerkmale

Merkmal	Hirudo (medizinisch)	Haemopis sanguisuga (falsch)
Orangefarbene Streifen	PRESENT — prominent dorsal stripes	COMPLETELY ABSENT — no orange coloration of any kind
Dorsale Farbe	Olivgrün mit deutlichem Streifenmuster	Einheitlich dunkelbraun bis fast schwarz; kein Muster
Ventrale Farbe	Blass, dunkel oder grün mit möglicher Fleckung	Schmutzig graugrün; einheitlich, ungemustert
Fütterungsart	Obligate hematophage (blood feeder); penetrates skin with sharp-toothed jaws	Predator/scavenger of invertebrates; tut NICHT feed on blood; cannot penetrate human skin
Speicheldrüsensekret	Rich Antikoagulans secretion (hirudin, destabilase, calin, etc.)	No Antikoagulans secretion; Speicheldrüsen poorly developed
Therapeutic value	FDA-zugelassenes Medizinprodukt	None — misidentification leads to therapeutic failure

Summary identification rule: The single most reliable field character for identifying a medizinischer Blutegel is the presence of orange-yellow dorsal longitudinal stripes. If dorsal stripes are absent, the specimen is NOT a medizinischer Blutegel — it may be Limnatis nilotica (dangerous) or Haemopis sanguisuga (harmless but useless). If in doubt, do not use the specimen clinically. FDA-zugelassenen leeches from verified suppliers eliminate this identification risk entirely.

Globale Vielfalt hämophager Blutegel

While the genus Hirudo dominates klinisch hirudotherapy, mehrere other hematophagous Blutegelart wurden used historisch or studied for their bioaktive Moleküle. Of approximately 650 freshwater Blutegelart worldwide, mehrere dozen are obligate blood feeders. The following are die am stärksten significant non-Hirudo hematophagous species in the medical and pharmacological literature.

Art	Gebräuchlicher Name	Bereich	Bedeutung
Hirudo nipponia	Japanischer medizinischer Blutegel	Japan, Korea, China	Used in traditionell East Asian medicine for Jahrhunderte. Closely related to H. medicinalis; ähnlich salivary composition. Studied for hirudin variants and neuartig Antikoagulans peptides
Haementeria officinalis	Südamerikanischer medizinischer Blutegel	Mittel- und Südamerika	Proboscis-bearing leech (feeds by inserting a proboscis rather than biting with jaws). Source of haementin, a fibrinogenolytic Enzym. Used in traditionell medicine across Latin America
Haementeria ghilianii	Amazonas-Riesenblutegel	Amazonas-Becken, Südamerika	The largest known hematophagous leech (up to 45 cm). Source of hementin (distinct from haementin), a potent fibrinolytic Enzym studied for thrombolytic applications. Historically significant in bioactive molecule discovery
Macrobdella decora	Nordamerikanischer medizinischer Blutegel	Östliches Nordamerika (Seen und Feuchtgebiete)	Source of decorsin — a potent glycoProtein IIb/IIIa (GP IIb/IIIa) integrin antagonist with an RGD motif (Seymour et al., 1990). Decorsin served as a structural model for antiplatelet drug development. Distinctively orange-spotted ventral surface
Hirudinaria manillensis	Asiatischer Büffelegel / Indischer medizinischer Blutegel	Süd- und Südostasien (Indien, Philippinen, Indonesien)	Used in Ayurvedic and traditionell Asian medicine. Source of tandem-hirudin (Hohmann et al., 2022) — an oligomeric hirudin superfamily member with two globular domains but no thrombin inhibition. Large species used clinically in India
Hirudo troctina	Nordafrikanischer medizinischer Blutegel	Marokko, Algerien, Tunesien, Iberische Halbinsel	Used in traditionell North African medicine. Closely related to the Hirudo medicinalis complex; molecular phylogenetics places it as a sister taxon. May represent an zusätzlich undescribed species-level lineage
Whitmania pigra	Chinesischer medizinischer Blutegel	China, Südostasien	One of the three Blutegelart listed in the Chinese Pharmacopoeia. Dried leech powder (水蛭, shuizhi) is a standard Traditional Chinese Medicine ingredient. Active pharmacological Forschung on Antikoagulans and anti-inflammatory peptides

The pharmacological diversity of hematophagous leeches extends far beyond Hirudo. Each lineage has evolved artspezifisch bioaktive Moleküle adapted to their particular vertebrate hosts and feeding strategies. This diversity represents an under-explored pharmacological resource: fewer than 20 species wurden characterized at the molecular level, leaving hundreds of potenziell drug leads unstudied.

Only Hirudo species are FDA-zugelassenen for klinischer Einsatz in the United States. The other hematophagous species listed above are of pharmacological and scientific interest, but none holds FDA 510(k) clearance. Their inclusion here is for educational completeness and to illustrate the broader context of leech diversity in welche die medizinischer Blutegel species complex sits.

Clinical Significance of Species Identification for Regulatory Compliance

The species problem in medizinischer Blutegel taxonomy is not merely an academic curiosity — es hat direct implications for regulatory compliance, klinisch documentation, Forschung reproducibility, and potenziell pharmacological variability.

Regulatorische Implikationen

510(k)-Dokumentation

All three aktuell 510(k) clearances reference „Hirudo medicinalis.“ The actual species supplied is predominantly H. verbana. This nomenclatural discrepancy is recognized in the scientific literature but has not triggered FDA enforcement action.

Risk level: Low for klinischer Einsatz (salivary profiles are broadly ähnlich per Babenko et al. 2020), but potenziellly significant for zukünftig artspezifisch regulatorische Anforderungen.

Forschungs-Reproduzierbarkeit

Published Studien that do not specify which species was actually used (or that use the generic label „H. medicinalis“ without molecular verification) may have reduced reproducibility.

Best Practice: Forschung publications should entweder verify species by COI barcoding or specify the supplier (which allows species inference — z. B., Ricarimpex supplies H. verbana).

Pharmakologische Variabilität

Whether species-level differences in salivary composition translate to clinically meaningful pharmacological differences is the central open question. Babenko et al. (2020) found verschiedeneial expression patterns despite qualitatively ähnlich repertoires.

Unresolved: No head-to-head klinisch trial comparing H. medicinalis vs H. verbana vs H. orientalis wurde conducted. Such a Studie would be expensive and logistically challenging given the rarity of H. medicinalis in commercial supply.

Institutional Quality Assurance Recommendations

Source verification: Procure leeches only from FDA-Lieferanten mit FDA-510(k)-Freigabe (Ricarimpex, Biopharm, Carolina Biological) to ensure consistent species and quality
Supply chain documentation: Maintain records of supplier, batch number, and date of receipt for each leech shipment as part of the device traceability record
Periodic molecular verification: Academic medical centers conducting Blutegeltherapie Forschung should consider periodic COI barcoding of incoming batches (empfohlen: annually or with each neu supplier contract)
Publication standards: Klinisch publications should specify the supplier name and, ideally, the verified species identity; use of the generic term „H. medicinalis“ should note the species ambiguity
CITES-Compliance: Institutions importing leeches from international suppliers must ensure compliance with CITES Appendix II trade documentation requirements for H. medicinalis

Schutzstatus & Handelsregulierung

The conservation status of medizinische Blutegel is a direct consequence of historisch over-harvesting. During the 19th-century „leech mania“ in European medicine, billions of leeches were collected from Wildpopulationen. France alone imported an estimated 41.5 million leeches in a single year (1833). This unsustainable harvest devastated Wildpopulationen, particularly of the northern H. medicinalis.

Regulation	Status	Practical Effect
CITES Anhang II	H. medicinalis gelistet	International trade requires export permits from country of origin; import documentation required. Captive-bred specimens from registered facilities (z. B., Ricarimpex) are exempt from some restrictions under CITES Resolution Conf. 10.16
Europäische Rote Liste	Gering gefährdet (H. medicinalis)	Wild collection restricted or verboten in many European countries. Germany, Switzerland, and Austria have specific protection statutes
EU-Habitat-Richtlinie	Anhang V	Member states must ensure that exploitation of H. medicinalis is compatible with maintaining favorable conservation status
Berner Konvention	Anhang III	Protected fauna; regulated exploitation under national legislation

Modern klinisch supply relies entirely on in Gefangenschaft gezüchtet leeches from FDA-zugelassenen facilities. Ricarimpex SAS maintains breeding populations of approximately 500,000 leeches in a pharmaceutical-grade facility. Biopharm’s Welsh facility ähnlichly breeds leeches unter kontrollierten Bedingungen. This closed-cycle aquaculture model eliminates pressure on Wildpopulationen while ensuring consistent supply quality.

CITES-Status bestätigt: Both H. medicinalis (CITES term 5353) and H. verbana (CITES term 5354) are explicitly listed in CITES Appendix II. H. orientalis is also covered under the broader Hirudo medicinalis complex listing. International trade in all diese Arten requires appropriate CITES export permits.

Evidence Summary — Taxonomy & Molecular Systematics

The following table summarizes key Studien in the taxonomy, molecular systematics, and species identification of medizinische Blutegel — from the founding monographs of the 18th and 19th Jahrhunderte through the molecular revolution of the 21st century.

Key Studien in Medicinal Leech Taxonomy & Species Identification
Studie	Design	Population (n=)	Intervention	Primäres Outcome	Ergebnis
Siddall ME et al. 2007	Molecular phylogenetic study	Hirudo specimens from European, Middle Eastern, and Central Asian populations (n=NR)	mtDNA COI sequencing + nuclear marker analysis across Hirudo populations previously classified as H. medicinalis subspecies	Species-level delimitation within the Hirudo medicinalis complex	Three distinct species confirmed: H. medicinalis, H. verbana, and H. orientalis. Genetic divergence exceeds subspecies threshold; reciprocal monophyly demonstrated on gene trees Landmark study that overturned the 3-subspecies model. Most commercial leeches labeled H. medicinalis are actually H. verbana
Babenko VV et al. 2020	Comparative transcriptomics (RNA-seq)	Salivary gland cells from H. medicinalis, H. verbana, and H. orientalis (n=NR)	RNA-seq of salivary gland tissue across all three medicinal leech species with draft genome assembly	Cross-species comparison of salivary transcriptome and bioactive molecule repertoire	Broadly similar salivary composition across 3 species: M12/M13 proteases, CRISP proteins, apyrase, adenosine deaminase, cystatins, hyaluronidase, ficolins all conserved. Differential expression patterns exist between species Draft genome sequences provided for all 3 species. First genome-level comparison of the medicinalis complex
Utevsky SY & Trontelj P 2005	Morphological and molecular taxonomy	Hirudo specimens from Turkey, Iran, Azerbaijan, and Central Asian regions (n=NR)	Integrative taxonomy combining morphological characters with molecular phylogenetic analysis	Formal description of a new species within the Hirudo medicinalis complex	H. orientalis sp. nov. formally described; distinguished by molecular divergence and subtle morphological differences from H. medicinalis and H. verbana Established the eastern species as taxonomically distinct. Widely used in CIS countries for hirudotherapy
Trontelj P & Utevsky SY 2012	Phylogeographic analysis	Hirudo medicinalis sensu lato populations across the Palearctic range (n=NR)	Multilocus phylogeography using mitochondrial and nuclear markers to resolve species boundaries and historical biogeography	Range delimitation and evolutionary history of the three medicinal leech species	Confirmed allopatric speciation pattern: H. medicinalis restricted to northern Europe (Scandinavia); H. verbana dominant in southern/southeastern Europe; H. orientalis across Turkey, Iran, and Central Asia. Contact zones identified in Balkans and Caucasus Refined the biogeographic ranges first suggested by Siddall et al. 2007
Kvist S et al. 2020	Genome assembly + bioinformatic analysis	H. medicinalis reference specimen for whole-genome sequencing (n=NR)	Draft genome assembly (176.96 Mbp, 19,929 scaffolds) with comprehensive gene annotation	Genomic architecture and identification of anticoagulant/antihemostatic gene families	15 anticoagulation factors and 17 antihemostatic proteins identified at genome level; first reference genome for the genus Hirudo Provides genomic foundation for resolving interspecific differences at sequence level
Whitman CO 1878	Systematic monograph	Family Hirudinidae specimens from global collections (n=NR)	Full morphological taxonomy establishing family-level classification of medicinal leeches	Formal establishment of Family Hirudinidae and subfamily framework	Family Hirudinidae formally erected; established morphological characters for genus-level and species-level identification still referenced in modern keys Foundational work expanded by Whitman 1886, 1887. Sawyer (1986) built directly on this framework
Sawyer RT 1986	Full taxonomic monograph	Global Hirudinea diversity — all known leech species at time of publication (n=NR)	Encyclopedic synthesis of leech taxonomy, morphology, ecology, and biogeography	Definitive taxonomic reference for Hirudinea classification and identification	~650 freshwater leech species cataloged; species-level keys provided. Established the standard reference framework that all subsequent molecular studies referenced for morphological characters The single most cited taxonomic reference in leech biology. Preceded molecular era by two decades
Moquin-Tandon A 1846	Morphological survey	H. medicinalis specimens across European populations, focusing on dorsal and ventral coloration (n=NR)	Systematic documentation of color pattern variation in medicinal leech populations	Enumeration and classification of intraspecific color morphs	19 distinct color variations documented within H. medicinalis; established that color alone is insufficient for species-level identification, but dorsal stripe pattern is the most reliable field character Historical reference still cited for phenotypic variability. Predated understanding that some variation reflected cryptic species
Moquin-Tandon A 1827	Systematic natural history monograph	Hirudinea specimens from French and Mediterranean collections (n=NR)	First comprehensive treatment of leech systematics as a standalone zoological group	Foundation of leech taxonomy as a scientific discipline	Established diagnostic morphological characters (jaw dentition, annulation, color patterns, sucker morphology) that remain in use; formal descriptions of multiple species and varieties Monographie de la famille des Hirudinées. Preceded Darwin; one of earliest rigorous invertebrate monographs
Shchegolev GG & Fedorova MS 0	Husbandry observation	Captive-raised H. medicinalis specimens under optimized laboratory conditions (n=NR)	Long-term captive rearing with controlled feeding to assess maximum growth potential	Maximum recorded size and weight for H. medicinalis	Specimen reached 44 cm body length and 38.8 g body weight — the largest documented medicinal leech on record Demonstrates exceptional growth plasticity in Hirudo; typical fasting adults are 10+ cm and 2-3 g

Evidenzlücken & Forschungsschwerpunkte

Despite the landmark molecular revision of medizinischer Blutegel taxonomy and the growing body of comparative genomisch data, mehrere important questions remain unresolved. The following gaps represent priorities for zukünftig research.

Pharmakologischer Artenvergleich

No head-to-head klinisch trial comparing H. medicinalis vs H. verbana vs H. orientalis for any indication
Whether verschiedeneial expression patterns (Babenko et al., 2020) translate to clinically meaningful differences in Antikoagulans potency, Blutungsdauer, or patient outcomes is unknown
Standardized in vitro bioassays comparing SDS potency artübergreifend wurden nicht published

Genomic & Proteomic Characterization

Current Entwurfs-Genoms (Kvist et al., 2020; Babenko et al., 2020) are fragmented; chromosome-level assemblies are needed for all three species
Proteomic quantification of salivary composition under standardized conditions artübergreifend is incomplete
Gene family evolution (duplication, pseudogenization) in Antikoagulans gene clusters remains uncharacterized
Population genomischs of in Gefangenschaft gezüchtet vs Wildpopulationen (genetic diversity, inbreeding, selection) is unstudied

Regulierung & Qualitätssicherung

FDA 510(k) nomenclature does not reflect aktuell taxonomy; no regulatory pathway exists for artspezifisch clearance
CITES-Anwendbarkeit auf H. verbana und H. orientalis (vs. H. medicinalis s. s.) ist in vielen Rechtsordnungen unklar
No validated quality control assay panel exists for species verification in incoming klinisch shipments
Retrospective molecular verification of species in landmark klinische Studien (which species was actually used?) would strengthen the evidence base

Biogeografie & Naturschutz

Contact zone dynamics between H. medicinalis, H. verbana, and H. orientalis in the Balkans and Caucasus are poorly characterized
Hybridization potenziell at range boundaries is unstudied — do hybrids occur in the wild, and if so, what are their pharmacological properties?
Wild population census data for all three species are outdated; aktuell Red List assessments may not reflect actual conservation status
H. troctina (Nordafrika) könnte eine vierte Art im Komplex darstellen — molekulare Beprobung reicht zur Klärung nicht aus

Undescribed Diversity

Of ~650 freshwater Blutegelart, fewer than 20 wurden molecularly characterized for bioaktive Moleküle
Tropical hematophagous leeches (Southeast Asia, Africa, South America) likely harbor neuartig pharmacological compounds adapted to verschiedene vertebrate hemostatic systems
The tandem-hirudin discovery from Hirudinaria manillensis (Hohmann et al., 2022) demonstrates that neuartig structural variants await discovery even in well-known species
Environmental DNA (eDNA) surveys could reveal undescribed hematophagous species in under-sampled regions

Forschungs- und Bildungshinweis

Die Informationen auf dieser Seite werden ausschließlich zu Bildungs- und Informationszwecken bereitgestellt und stellen keine medizinische Beratung, Diagnose oder Behandlungsempfehlung dar. Die klinischen Evidenzzusammenfassungen geben die veröffentlichte, peer-reviewte Literatur wieder und implizieren keine therapeutische Wirksamkeit außerhalb FDA-zugelassener Kontexte.

Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt. Anwendungen im Untersuchungs- und Off-label-Bereich werden als solche durchgehend gekennzeichnet. Praktiker sollten vor der klinischen Anwendung die aktuellen FDA-Richtlinien, institutionelle Protokolle und geltende bundesstaatliche Vorschriften konsultieren.

ASH unterstützt eine rigorose, evidenzbasierte Bewertung aller Hirudotherapie-Anwendungen durch kontrollierte klinische Studien und peer-reviewte Forschung.